PANITUMUMAB
Healthy
Universitaire Ziekenhuizen KU Leuvenmonoclonal_antibodyPhase 4 / ApprovedActive
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 73/ 100
Competitive context
8 Active assets in the Healthy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Benserazide University Hospital Muenster | Phase 4 | B |
Doxycycline Universitaire Ziekenhuizen KU Leuven | Phase 4 | B |
Humulin R Columbia University | Phase 1 | CCC |
Sra-333 Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 | CC |
gla5pr GL Pharm Tech Corporation | Phase 1 | CC |
View all 25 →
Same molecule, other indications
PANITUMUMAB is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →